External beam radiotherapy with or without californium-252 neutron brachytherapy for treatment of recurrence after definitive chemoradiotherapy

Wen-an Wu1,2,3, Yi-ping Yang2,3, Jing Liang2, Jin Zhao2, Jian-sheng Wang1,2,3 & Jia Zhang1,2,3

We aimed to evaluate the application of external beam radiotherapy (EBRT) combined with californium-252 (252Cf) neutron intraluminal brachytherapy (NBT) in patients with local recurrent esophageal cancer after definitive chemoradiotherapy (CRT). Sixty-two patients with local recurrent esophageal squamous cell carcinoma after definitive CRT were retrospectively analyzed; 31 patients underwent NBT+EBRT, and 31 received EBRT alone. The response rate; 1-, 2-, and 3-year overall survival rates; and adverse event occurrence rates were compared between these two patient groups. The response rate was 83.87% (26/31) in the NBT+EBRT group and 67.74% (21/31) in the EBRT group (p < 0.001). The 1-, 2-, and 3-year overall survival rates were 80.6%, 32.3%, and 6.5%, respectively, in the EBRT group, with a median survival time of 18 months. The 1-, 2-, and 3-year overall survival rates were 83.8%, 41.9%, and 6.9%, respectively, in the NBT+EBRT group, with a median survival time of 19 months. The differences between the groups were not significant (p = 0.352). Regarding acute toxicity, no incidences of fistula or massive bleeding were observed during the treatment period. The incidences of severe and late complications were not significantly different between the two groups (p = 0.080). However, the causes of death for all patients differed between the groups. Our data indicate that 252Cf-NBT+EBRT produces favorable local control for patients with local recurrent esophageal cancer after CRT, with tolerable side effects.

Abbreviations

252Cf  Californium-252
ARS  After-recurrence survival
CR  Complete response
CRT  Chemoradiotherapy
CT  Computed tomography
CTV  Clinical target volume
EBRT  External beam radiotherapy
GTV  Gross tumor volume
NBT  Neutron intraluminal brachytherapy
PR  Partial response
PTV  Planning target volume
RFS  Recurrence-free survival
RT  Radiotherapy
SD  Stable disease
RBE  Relative biological effectiveness

1The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China. 2The Shaanxi Provincial Tumor Hospital, Xi'an 710061, China. 3These authors contributed equally: Wen-an Wu and Yi-ping Yang. 5,6email: wangjsh@mail.xjtu.edu.cn; zhangjiaxjtu@xjtu.edu.cn
In 2014, approximately 200,000 new patients in China were diagnosed with local recurrent esophageal cancer, and the prevalence of this disease is expected to be younger and increase. Squamous cell carcinoma is the predominant histological subtype and likely develops in the middle and upper thoracic esophagus. Esophagectomy is the standard treatment strategy for localized esophageal cancer. For advanced esophageal carcinoma or patients who decline or cannot tolerate surgery, definitive radiotherapy (RT) is an alternative.

The most common treatment failure for esophageal cancer after definitive RT or chemoradiotherapy (CRT) is local recurrence. The recurrence rate after definitive RT, CRT and/or surgery reaches 70%, and the 5-year survival rate is also low. Local recurrence in the radiation field is the most important reason for radiotherapy failure. Furthermore, most patients with recurrence are no longer eligible for surgery. Thus, repeated irradiation is required for some right patients. The advantage of RT as a primary treatment for esophageal carcinoma or its local recurrence has been widely demonstrated. However, the prescription dose to reirradiate a target is limited by dose constraints of the surrounding normal tissue, and the local recurrence of esophageal carcinoma after definitive RT or chemoradiotherapy (CRT) is resistant to conventional photon radiotherapy. Brachytherapy is appropriate for the local recurrence of esophageal cancer after RT/CRT due to the high doses of radiation to the tumor and the low doses to nearby normal tissues. Evidence from randomized trials has revealed that the outcome of single-fraction intraluminal brachytherapy is better than that of stents, in which intraluminal brachytherapy improves dysphagia and quality of life associated with the delayed onset of symptomatic relief.

On the other hand, californium-252 (252-Cf) neutron intraluminal brachytherapy (NBT) is a high linear energy transfer RT approach effective for treating radioresistant cancer and intracavitary cancers of the cervix, colon/rectum and esophagus when combined with external beam RT (EBRT).

To date, no multicenter, randomized prospective trials have compared the efficacy of NBT+EBRT and EBRT for the treatment of esophageal carcinoma and recurrence after definitive CRT. Accordingly, we conducted a retrospective study to evaluate the morbidity and effectiveness of EBRT combined with 252-Cf-NBT in treating patients with local recurrent esophageal carcinoma after definitive CRT.

Materials and methods

General clinical data. The present study was approved by the Protection of Human Subjects Committee of Shannxi Provincial Tumor Hospital (No. 2010–007) and complied with the Declaration of Helsinki. Informed consent was obtained from all patients.

A total of 62 patients with local recurrent esophageal carcinoma received definitive CRT between August 2010 and August 2018. The inclusion criteria were as follows: (1) patients who received definitive CRT as the initial treatment for esophageal cancer, (2) patients with squamous cell carcinoma, (3) patients with pathologically confirmed local recurrence without local or distal lymph node recurrence, (4) no salvage esophagectomy after recurrence, (5) no serious medical history or illness, and (6) no perforation of the esophagus or deep ulcer of the esophagus. All patients were divided into two groups based on the treatment received: the NBT+EBRT group, patients who received EBRT combined with 252-Cf-NBT; and the EBRT group, patients who received only EBRT. The clinical profiles and manifestations of all patients are summarized in Table 1.

Treatment. Group: EBRT. Intensity-modulated RT was delivered to patients in the EBRT group. First, simulation CT scanning was performed, and images were transferred to a planning system. Second, physicians delineated the gross tumor volume (GTV) utilizing information from an endoscopic investigation and magnetic resonance imaging (MRI). Margins of 0.8 cm and 1.0 cm along the superior and inferior directions were given to the GTV for the clinical target volume (CTV). A margin of 0.5 cm in all directions was given to the CTV for the planning target volume (PTV). A dose of 54–60 Gy was prescribed for salvage RT, with 1.8–2 Gy/f for 5 f./w (30 fractions total).

Group: EBRT+NBT. During the treatment period, EBRT was carried out with intensity-modulated RT. The GTV was determined according to the endoscopic investigation and magnetic resonance imaging (MRI). The total dose via EBRT was 41.4–46 Gy, four fractions/week, one fraction/day, and 1.8–2.0 Gy/fraction, for a total of 23 fractions.

NBT was implemented with a 252-Cf-based LZH-1000 intracavitary radiotherapy machine (Shenzhen, China). Californium-252 has a half-life of 2.65 years and, on decay, emits $2.31 \times 10^6$ neutrons/s/µg and $1.32 \times 10^7$ gamma photons/s/µg. The mean neutron energy was 2.2 meV, and the mean energy of gamma photons was 0.8 meV. Liu et al described the relative biological effectiveness (RBE) value of neutrons. Both the RBE value of the neutron and algebraic formula were included in the treatment plan of the NBT system. The source applicator includes a water balloon surrounding the source. The water balloon is 12 cm long, and the diameter can vary. The water balloon is an important part of the source applicator because it can keep the source close to the tumor but away from the adjacent normal epithelium. The position of the source capsule was determined on the X-ray image and then used as input for the treatment system. The reference point of the prescription for NBT was on the transverse plane 10 mm from the center point of the source capsule. The total dose via NBT was 12 Gy/12 Gy-ecq/3 f., and 4 Gy-ecq/1 f./1 w.

Organs at risk (OARs). The dose limit was 45 Gy for initial CRT in the spinal cord and 20 Gy for salvage RT. The volume fractions of 5 Gy (V5) and 20 Gy (V20) in the lungs were restricted to 60% and 28%, respectively, for initial CRT and 55% and 25%, respectively, for recurrence therapy.

Chemotherapy. Concurrent chemotherapy was recommended for all patients with local recurrent esophageal cancer after radical chemoradiotherapy. Adjuvant or induction chemotherapy was not recommended. All patients completed two cycles of 51 concurrent chemotherapy.
Toxicity assessment and follow-up. Weekly blood tests and other examinations were performed throughout the course of treatment. We recorded all treatment-related complications. The adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Upon the completion of treatment, follow-up examinations were performed every 3–6 months. Repeated CT, barium swallow fluoroscopy and endoscopy were performed to evaluate the tumor responses and nodal diseases.

Statistical analysis. All statistical analyses were performed using SPSS software (version 20.0). The continuous and categorical variables of these two groups were compared to baseline characteristics using t-tests and chi-square tests. Overall survival (OS) was defined as the time from the receipt of treatment to death or the last follow-up. Recurrence-free survival (RFS) was defined as the time from the receipt of treatment to the pathological confirmation of recurrence. Last, after-recurrence survival (ARS) was defined as the time from the pathological confirmation of recurrence to death. The Kaplan–Meier method was used to generate survival curves, and the curves were compared using log-rank tests. Factors that influenced survival were determined using Cox's proportional hazards regression model. P < 0.05 was considered statistically significant.

Results

Responses to treatment. All patients exhibited a response to treatment. In the NBT+EBRT group, 84% of patients achieved complete response (CR) or partial response (PR), while the remaining 16% of patients achieved stable disease (SD). Furthermore, patients in the NBT+EBRT group exhibited significantly better responses than those in the EBRT group.

Patient survival. The follow-up period ranged within 6–72 months, with a median follow-up of 23 months that ended in August 2018. During the follow-up period, all patients died. For the entire study population, OS ranged from 6–49 months, with a median OS duration of 19 months, and the 1-, 2- and 3-year OS rates were

| Characteristics | EBRT (N) | NBT+EBRT (N) | p value |
|-----------------|---------|--------------|---------|
| Sex             |         |              | 0.758   |
| Male            | 18      | 17           |         |
| Female          | 13      | 14           |         |
| Age (years)     |         |              | 1.095   |
| ≤50             | 16      | 14           |         |
| >50             | 15      | 17           |         |
| Location of tumor |       |              | 0.936   |
| Upper           | 12      | 14           |         |
| Middle          | 16      | 12           |         |
| Lower           | 3       | 5            |         |
| Initial length  |         |              | 0.625   |
| ≤5 cm           | 18      | 17           |         |
| >5 cm           | 13      | 14           |         |
| Pathological grade |     |              | 0.085   |
| I               | 5       | 7            |         |
| II              | 20      | 19           |         |
| III             | 6       | 5            |         |
| Initial clinical stage |   |              | 0.785   |
| II              | 14      | 12           |         |
| III             | 17      | 19           |         |
| Initial ECOG-PS |         |              | 0.634   |
| 0–1             | 20      | 19           |         |
| 2               | 11      | 12           |         |
| 3               | 0       | 0            |         |
| Initial radiation dose(GY) |       |              | 0.082   |
| ≥60 Gy          | 28      | 29           |         |
| <60 Gy          | 3       | 2            |         |
| RFS             |         |              | 0.093   |
| ≥12 months      | 19      | 20           |         |
| <12 months      | 12      | 11           |         |

Table 1. Patients characteristics (N = 62). EBRT external beam radiotherapy, ECOG-PS Eastern Cooperative Oncology Group performance status, NBT neutron intraluminal brachytherapy, RFS recurrence-free survival.
83.8%, 37% and 8%, respectively. Moreover, the median RFS duration was 12 months, while the median ARS duration was 11 months.

For patients in the EBRT group, the 1-, 2- and 3-year OS rates were 80.6%, 32.3% and 6.5%, respectively, and the median OS duration was 18 months. For patients in the NBT+EBRT group, the 1-, 2- and 3-year OS rates were 83.8%, 41.9%, and 6.9%, respectively (Fig. 1), and the median OS duration was 19 months. There was no significant difference in the median OS duration between these two groups ($P = 0.352$).

The 6-month and 1-year ARS rates in the NBT+EBRT group were 74.2% and 61.3%, respectively. On the other hand, the 6-month and 1-year ARS rates in the EBRT group were 38.7% and 25.8%, respectively. There was no significant difference between these two groups ($P = 0.374$, Fig. 2).

Though not statistically significant ($p = 0.667$ with a 95% confidence interval), the median FRS duration for the NBT+EBRT group was 13 months (10.2 to 13.9 months), whereas that for the EBRT alone group was 12 months (10.6 to 14.6 months). These mean values suggest that EBRT alone is nonsignificantly superior to NBT+EBRT.

For patients whose recurrence occurred at $\geq 12$ months, the median OS duration was 26 months, while the median OS duration for early recurrence ($< 12$ months) was 13.5 months ($P < 0.001$, Fig. 3). Furthermore, the median ARS duration for late recurrence was 10 months, while the median ARS duration for early recurrence

---

**Figure 1.** Overall survival curves of patients treated with external beam radiotherapy (EBRT) versus those who received neutron intraluminal brachytherapy (NBT) plus EBRT (log-rank $p = 0.352$).

**Figure 2.** After-recurrence survival in patients who received external beam radiotherapy (EBRT) versus those who received neutron intraluminal brachytherapy (NBT) plus EBRT (log-rank $p = 0.374$).
was six months, and the difference was marginally significant \( (P = 0.053) \). The multivariate analysis of factors revealed that salvage RT and RFS are significant predictors of OS (Table 2).

Table 3 shows the detailed death data of all patients at the end of follow-up. Regarding the causes of death in all patients, the difference between the two groups was statistically significant \( (P < 0.001) \).

**Treatment-related toxicity.** NBT and/or EBRT were completed by all patients. Throughout the treatment period, no perforations or massive bleeding was observed. Among these patients, 27 (43.5%) developed grade 2 hematologic toxicities, while 40 (64.5%) were diagnosed with grade 2 or higher esophagitis, as expressed by clinical odynophagia. After four to six weeks of treatment, three-quarters of patients resumed normal swallowing, while merely 3.6% of patients had residual dysphagia that required intermittent dilatation. Two patients (3.2%) had grade 2 or above irradiation dermatitis. During the follow-up period, four patients (6.5%) suffered from fistulas, and five patients (8.1%) had massive bleeding upon local recurrence. Moreover, four patients (12.9%) in the EBRT group exhibited radiation pneumonitis higher than grade 3, and all died of severe lung infection. Because patients experienced short survival durations after recurrence, spinal cord damage was not observed. Overall, no significant difference in acute toxicities or late complications was found between these two groups (Table 4).

**Discussion**

Definitive CRT or RT is a treatment alternative for patients with unresectable advanced cancer or patients who refuse surgery. However, merely 30%-62% of patients who receive CRT achieve pathological complete response. More importantly, the recurrence rate of this approach is high. Esophageal carcinomas are often metachronous or occur with multiple malignancies\(^1\). Recurrence in esophageal carcinomas remains a major challenge. Studies have reported that for surgical approaches, the local recurrence rate is 12.1%, and the incidence of lymph node metastasis is 18.2\(^\text{nd}\). However, the local recurrence rate after RT/CRT could reach as high as 78.4\%, with a 33.3% recurrence rate of lymph node metastasis\(^1\). The method, which depends on the anatomical location of the recurrent lesion, initial treatment strategy and tumor response, influences salvage treatment. The optimal salvage treatment remains to be elucidated. For patients with local failure after CRT, salvage surgery has been suggested. However, the rates of complications and mortality are high. Furthermore, salvage surgery is not recommended for patients with locally advanced, nonresectable, or inoperable tumors\(^\text{4-7}\). Some papers have reported that EBRT+NBT can improve PFS and OS in patients with advanced cervical and esophageal carcinomas\(^\text{18-19}\). Zhi-guo Zhou\(^\text{20}\) reported that compared to chemotherapy, gastrostomy and stent implantation, reirradiation could improve OS in patients with local recurrence of esophageal carcinoma after definitive RT or chemoradiotherapy (CRT). The present retrospective analysis revealed that using NBT as an adjuvant treatment for recurrent esophageal cancer in conjunction with EBRT was effective and well tolerated by patients. This treatment approach improved local control because neutrons are more effective than photons in killing radioresistant tumor cells and do not increase the rate of late and severe complications. However, there was no significant improvement in OS. Two reasons may explain these results. The first may be due to the highly similar irradiation dose. The second may be due to the relatively small cohort.

The RTOG9405/INT 0123 trial reported that compared to the standard irradiation dose for esophageal carcinoma (50.4 GY), the higher dose (64.8 GY) did not improve survival or local control\(^\text{15}\). However, other papers reported that the standard irradiation dose of approximately 60 GY for the recurrence of esophageal carcinoma following surgery could improve survival\(^\text{21}\). Tagger et al.\(^\text{21}\) reported that high brachytherapy doses may improve
overall survival. Therefore, with a high reirradiation dose in our cohort, the dose of EBRT was 54–60 GY/30 f., and that of NBT+EBRT was 12 Gy-eq/3 f. + 41.4 Gy/23 f. or 12 Gy-eq/3 f. + 46 Gy/23 f.

Consistent with previous studies, recurrence markedly shortened the survival duration. The median OS duration was 19 months in the nonrecurrence group and 9.25 months in the recurrence group. Notably, more than 45% of patients relapsed within one year after irradiation, with a 1-year local control rate of 64.5%. Ishihara et al. revealed similar findings, in which 82% of recurrences developed within 21 months of CRT. The 1-, 2- and 3-year OS rates of recurrent patients who received salvage RT were 83.8%, 37% and 8%, respectively, which were

| Characteristics       | Number | Median OS (months) | Log-rank test | Univariate |
|-----------------------|--------|--------------------|---------------|------------|
|                       |        |                    | p value       | p value    |
| Sex                   |        |                    | 0.625         | 0.765      |
| Male                  | 35     | 18                 |               |            |
| Female                | 27     | 17                 |               |            |
| Age (years)           |        |                    | 0.752         | 0.654      |
| ≤ 50                  | 30     | 20                 |               |            |
| > 50                  | 32     | 19                 |               |            |
| Tumor location        |        |                    | 0.156         | 0.235      |
| Upper                 | 26     | 15                 |               |            |
| Middle                | 28     | 17                 |               |            |
| Lower                 | 8      | 19                 |               |            |
| Initial length        |        |                    | 0.023         | 0.164      |
| ≤ 5 cm                | 35     | 21                 |               |            |
| > 5 cm                | 27     | 16                 |               |            |
| Pathological grade    |        |                    | 0.102         | 0.274      |
| I                     | 12     | 20                 |               |            |
| II                    | 39     | 18                 |               |            |
| III                   | 11     | 15                 |               |            |
| Initial clinical stage|        |                    | 0.412         | 0.657      |
| II                    | 26     | 20                 |               |            |
| III                   | 36     | 17                 |               |            |
| Initial ECOG-PS       |        |                    | 0.758         | 0.458      |
| 0–1                   | 39     | 19                 |               |            |
| 2                     | 23     | 18                 |               |            |
| 3                     | 0      |                    |               |            |
| Initial radiation dose|        |                    | 0.532         | 0.178      |
| ≥ 60 Gy               | 57     | 19                 |               |            |
| < 60 Gy               | 5      | 18                 |               |            |
| RFS                   |        |                    | 0.001         | 0.001      |
| ≥ 12 month            | 39     | 26                 |               |            |
| < 12 month            | 23     | 13.5               |               |            |
| Group                 |        |                    | 0.352         | 0.473      |
| NBT+EBRT              | 31     | 19                 |               |            |
| EBRT                  | 31     | 18                 |               |            |

Table 2. Prognostic factors evaluated by log-rank test survival analysis. EBRT external beam radiotherapy, ECOG-PS Eastern Cooperative Oncology Group performance status, NBT neutron intraluminal brachytherapy, RFS recurrence-free survival.

| Cause of death          | NBT+EBRT, N (%) | EBRT N (%) | p value |
|-------------------------|-----------------|------------|---------|
| Local failure           | 3 (9.7)         | 5 (16)     | 0.001   |
| Fistulas/massive bleeding| 5 (16.3)       | 4 (12.9)   |         |
| Metastasis              | 22 (71)         | 15 (48.4)  |         |
| Lung infection          | 1 (3.2)         | 7 (22.6)   |         |

Table 3. Causes of death (N = 62). EBRT external beam radiotherapy, NBT neutron intraluminal brachytherapy.
promising when compared with those reported in other studies. Yamashita et al. reported that curative surgery on the locoregional recurrence of esophageal cancer yielded a median survival time of 13.8 months and a 1-year survival rate of 56%. Furthermore, Jing et al. reported that 5-fluorouracil concurrent with CRT yielded a 3-year survival rate of 56.3%. Nicolay et al. reported that salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients yielded a median local PFS duration of 9.8 months and 1- and 2-year survival rates of 31.5% and 17.5%, respectively. Last, Amandeep S Taggar et al. reported that endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer yielded a median survival time of 20.9 months and a 1-year survival rate of 78%. The variation in these findings might be attributed to the conditions at the time of treatment, the locations of recurrent lesions and alternative therapies received by patients. The survival rate was low in patients who experienced recurrence at or within one year after radical RT/CRT. The growth rate of recurrent tumors is likely associated with the time of recurrence. In particular, early recurrences may arise from fast-growing or hypoxic and therapy-resistant tumor cells. Compared with X-ray, californium-252 neutron brachytherapy has a high-LET nature, making it much more effective in killing hypoxic and therapy-resistant tumor cells. So in our study the EBRT+NBT may be suited to patients with short-term recrudescence or the nearby normal tissues dose must be low, and received a significantly lower IMRT (41.4–46 Gy, four fractions/week, one fraction/day, and 1.8–2.0 Gy/fraction, for total of 23 fractions), this can be addressed by reference to the additional dose from the NBT. We will further study the effect of Californium-252 neutron brachytherapy in patients with early recurrence.

In the present study, the main causes of death were different between the NBT+EBRT group and the EBRT group. The NBT+EBRT group had metastasis, and the EBRT group had local regional recurrence. It was posited that high linear energy transfer 252Cf-NBT is superior to conventional RT (X-ray) for esophageal cancers, which are generally radioresistant or hypoxic. A neutron dose to nearby normal tissues can be reduced by water injection into the source applicator. Salvage RT was completed without radiation myelitis or spinal cord damage in all patients in the NBT+EBRT group, especially in patients with short-term recrudescence or those in whom nearby normal tissues doses had to be low to tolerate therapy. However, there was no significant difference in the rate of acute toxicities or late complications between these two groups.

**Conclusion**

The limitations of the present study were its retrospective nature and the relatively small cohort. However, NBT+EBRT for recurrent esophageal carcinoma after CRT is an effective treatment option, and it is especially suitable for patients with short-term recrudescence. Patients who were treated with 252Cf-NBT in combination with EBRT achieved better local control.

Received: 29 May 2020; Accepted: 19 November 2020
Published online: 01 December 2020

**References**

1. Siegel, R., Naishadham, D. & Ahmedin, J. Cancer statistics, 2013. *CA Cancer J. Clin.* 63, 11–30 (2013).
2. Ma, L. et al. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae. *Clin. J. Cancer.* 36, 26–33 (2017).
3. Ma, D. Y. et al. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. *Radiat. Oncol.* 9, 28 (2014).
4. Tepper, J. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J. Clin. Oncol.* **26**, 1086–1092 (2008).

5. Kato, K. et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). *Int. J. Radiat. Oncol. Biol. Phys.* **81**, 684–690 (2011).

6. Chao, Y. K. et al. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. *Eur. J. Surg. Oncol.* **35**, 289–294 (2009).

7. Kam, S. W. H. et al. Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients: a retrospective analysis. *Brachytherapy* **14**, 531–536 (2015).

8. Yorozu, A., Dokiya, T. & Oki, Y. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* **45**, 271–275 (1999).

9. Liu, H., Wang, Q., Jia, X., Liu, B. & Wang, C. K. Early-stage esophageal squamous cell carcinoma treated with californium-252 neutron brachytherapy: clinical report on 16 cases. *Tumori* **99**, 172–175 (2013).

10. Liu, H. et al. Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: long-term treatment results. *Brachytherapy* **13**, 514–521 (2014).

11. Welsh, J. et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. *Cancer* **118**, 2632–2640 (2012).

12. Okamoto, K. et al. Therapeutic strategies with multidisciplinary local therapy for postoperative recurrence of esophageal cancer. *GanTo Kagaku Ryoho* **43**, 1490–1492 (2016).

13. Nakajima, T. et al. Definitive chemoradiotherapy for recurrent esophageal cancer after curative esophagectomy. *GanTo Kagaku Ryoho* **13**, 1564–1566 (1986).

14. Takemura, M. et al. Clinical outcomes of local therapy for lymph node recurrence after radical esophagectomy for esophageal cancer. *GanTo Kagaku Ryoho* **43**, 1493–1495 (2016).

15. Muto, M. & Yano, T. Photodynamic therapy for local recurrence of esophageal cancer after chemoradiotherapy. *GanTo Kagaku Ryoho* **43**, 1053–1057 (2016).

16. Liu, S. et al. Prognostic factors for locoregional recurrence in patients with thoracic esophageal squamous cell carcinoma treated with radical two-field lymph node dissection: results from long-term follow-up. *Ann. Surg. Oncol.* **24**, 966–973 (2017).

17. Farnella, E. et al. Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer. *J. Surg. Oncol.* **114**, 833–837 (2016).

18. Gaspar, L. E. et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. *Cancer* **88**, 988–995 (2000).

19. Lei, X. et al. Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results. *Int. J. Radiat. Oncol. Biol. Phys.* **81**, 1264–1270 (2011).

20. Zhou, Z. G. et al. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. *Radiat. Oncol.* **10**, 54 (2015).

21. Minsky, B. D. et al. INT 0123 (Radiation Therapy Oncology Group 9405) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J. Clin. Oncol.* **20**, 1167–1174 (2002).

22. Ravi, S. H., Burmeister, B., Harvey, J. A., Smithers, M. & Thomas, J. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma afterprimary surgery: retrospective review. *J. Med. Imag. Radiat. Oncol.* **52**, 583–587 (2009).

23. Taggar, A. S. et al. Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. *Brachytherapy* **17**, 621–627 (2018).

24. Ishihara, R. et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* **76**, 123–129 (2018).

25. Gaspar, E. L. et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. *Int. J. Radiat. Oncol. Biol. Phys.* **37**, 593–599 (1997).

26. Yamashita, H. et al. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. *Dis. Esophagus* **18**, 215–220 (2005).

27. Ingu, K. et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. *BMC Cancer* **12**, 542 (2012).

28. Nicolay, N. H. et al. High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer. *Strahlenther. Onkol.* **192**, 458–466 (2016).

**Acknowledgements**

This work was supported by natural science basic research plan in Shaanxi Province of China (No. 2017M8158). Wen-an WU collected the data, participated in the study, and drafted the manuscript. Jing LIANG collected the data. Jin ZHAO collected the data. Yi-ping YANG designed the study and established the treatment plan. Jian-sheng WANG and Jia ZHANG conceived the study, participated in its design and coordination, and helped draft the manuscript. All authors have read and approved the final manuscript.

**Author contributions**

W.W. performed the data collection, participated in the study, and drafted the manuscript. J.L. performed the data collection. I.Z. participated in the data collection. Y.Y. participated in the design of the study and performed the treatment planning. J.W. and J.Z. conceived the study, participated in its design and coordination, and helped in drafting the manuscript. All authors have read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence**

Requests for materials should be addressed to J.W. or J.Z.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
